The distributions of the end-simulation adolescence-limited proportion when (a) <i>k</i> is increased or decreased by 50%, (b) <i>c</i> is increased or decreased by 50%, (c) <i>γ</i> is increased or decreased by 50%, and (d) Δ<i>e</i> is increased or decreased by 50%, compared against the benchmark distribution <i>F</i>(<b>p</b>₀) for the parameters shown in Table 1. by Jia Ning Leaw (752775)

Decreasing fluconazole susceptibility of clinical South African <i>Cryptococcus neoformans</i> isolates over a decade by Serisha D. Naicker (8648370)

The fraction of predicted heterozygotes that are set to “No Call” by RHA decreases as the size of the heterozygote cluster increases. by Orna Mizrahi-Man (42539)

Expression of ApoB-50 decreased lipid accumulation and inhibited HCV production. by Bei Wang (116772)

NFκB-p50 knockdown decreases CD44 expression. by Shannon M. Smith (115335)

Prevalence and anatomic level of stenosis ≥ 50% in either limb. by O. Stivalet (6890189)

Affinity analysis results (with a confidence level above 50%). by Marta R. Jabłońska (8491404)

Predicting pattern diversity decreases as a function of and . by Selim Haj Ali (21222613)

“…<p>For 50 Erdős-Rényi graphs with 30 nodes and 70 edges, we split the results into two columns according to the two initial degenerate unstable eigenmodes  +  : on the left, (if ), and on the right, (if ). …”

Effectiveness of interventions to decrease hesitancy. by Maximilian Nicolaus Burger (12969212)

Damsin (D) and ambrosin (A) treatment decreases the CSC population. by Wendy Soria Sotillo (4408105)

LPS decreases only T cell proliferative response to OKT3. by Fanny Poujol (834338)

BMT decreases HFD-induced weight gain associated with decreased preadipocyte number and insulin secretion by Saeed Katiraei (3956147)

EC50 and percentage decrease in intracellular <i>Listeria</i> viability for effective compounds. by Marie-Eve Charbonneau (5658799)

Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”

Variable importance plot (mean decrease accuracy and mean decrease Gini). by Fernando Martinez-Taboada (8655132)

Primary endpoint analysis, i.e., time to first occurrence of combined event of 50% decrease in eGFR or ESRD. by Rozita Mohd (7411322)

Surface tension versus time of the MHS solution (50 mM) and LNC dispersion containing 50 mM MHS as determined by drop tensiometry. by Celia R. A. Mouzouvi (4347937)

Definitions of the features selected [50]. by Yu Zhang (12946)

Topography of the relationship between the change in alpha power decrease and the change in M50 gating ratio. by Tzvetan Popov (315385)

“…B: Relationship between change in alpha power decrease (abscissa, negative values indicate improvement) and pre-to-post-training change in M50 gating ratio (ordinate, positive values indicate changes towards normal, that is, smaller gating ratio) by patient training group based on the ROI in 4A.…”

Cell adhesion to fibronectin is decreased with 50 µM 4N1K treatment. by Pascal Leclair (566971)